HALF LIFE OF METOPROLOL FULL
HALF LIFE OF METOPROLOL PLUS

No evidence of impaired fertility due to metoprolol tartrate was observed in a study performed in rats at doses up to 24 times, on a mg/m 2 basis, the daily dose of 200 mg in a 60-kg patient.

This 21-month study was repeated in CD-1 mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type of tumor.ДЄll genotoxicity tests performed on metoprolol tartrate (a dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity test, and a nucleus anomaly test in somatic interphase nuclei) and metoprolol succinate (a Salmonella/mammalian-microsome mutagenicity test) were negative.

HALF LIFE OF METOPROLOL PLUS

There was no increase in malignant or total (benign plus malignant) lung tumors, nor in the overall incidence of tumors or malignant tumors.

In a 21-month study in Swiss albino mice at three oral dosage levels of up to 750 mg/kg/day (18 times, on a mg/m 2 basis, the daily dose of 200 mg for a 60-kg patient), benign lung tumors (small adenomas) occurred more frequently in female mice receiving the highest dose than in untreated control animals. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli and a slight increase in biliary hyperplasia. In 2-year studies in rats at three oral dosage levels of up to 800 mg/kg/day (39 times, on a mg/m 2 basis, the daily dose of 200 mg for a 60 kg patient), there was no increase in the development of spontaneously occurring benign or malignant neoplasms of any type. Long-term studies in animals have been conducted to evaluate the carcinogenic potential of metoprolol tartrate. The precise mechanism of action of Metoprolol tartrate in patients with suspected or definite myocardial infarction is not known.ДЎ3.1 Carcinogenesis, Mutagenesis, Impairment of Fertility (2) In asthmatic patients, metoprolol reduces FEV 1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta 1-receptor blocking doses. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine. The relative beta 1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta 2-mediated vasodilating effects of epinephrine.

Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol is a beta 1-selective (cardioselective) adrenergic receptor blocking agent.

HALF LIFE OF METOPROLOL FULL

FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1Д›radycardia 5.2 Heart Failure 5.3Д›ronchospastic Disease 5.4 Pheochromocytoma 5.5 Peripheral Vascular Disease 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Post-Marketing Experience 7 DRUG INTERACTIONS 7.1Дњatecholamine Depleting Drugs and Monoamine Oxidate (MAO) Inhibitors 7.2Дћpinephrine 7.3ДњYP2D6 Inhibitors 7.4Дќigitalis, Clonidine, and Calcium Channel Blockers and Other Drugs that Decrease Heart Rate 7.5Дќrugs that Decrease Blood Pressure 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed.

Half life of metoprolol